scholarly journals Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation

2019 ◽  
Vol 25 (6) ◽  
pp. e204-e208 ◽  
Author(s):  
Nico Gagelmann ◽  
Diderik-Jan Eikema ◽  
Liesbeth C de Wreede ◽  
Linda Koster ◽  
Christine Wolschke ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Polycythemia Vera ◽  
Cell Transplantation ◽  
Essential Thrombocythemia ◽  
Allogeneic Stem Cell Transplantation ◽  
Scoring System ◽  
Prognostic Model ◽  
International Prognostic Scoring System ◽  
Prediction Of Outcome

Utility of a Prognostic Scoring System for Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia

2003 ◽  
Vol 109 (3) ◽  
pp. 119-123 ◽  
Author(s):  
Muzaffar H. Qazilbash ◽  
Marcel P. Devetten ◽  
Jame Abraham ◽  
Joseph P. Lynch ◽  
Charles L. Beall ◽  
...  
Keyword(s):  
Stem Cell ◽  
Chronic Myeloid Leukemia ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Scoring System ◽  
Myeloid Leukemia

Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies

2012 ◽  
Vol 30 (36) ◽  
pp. 4533-4540 ◽  
Author(s):  
Gandhi Damaj ◽  
Alain Duhamel ◽  
Marie Robin ◽  
Yves Beguin ◽  
Mauricette Michallet ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Underlying Disease ◽  
International Prognostic Scoring System ◽  
Cytoreductive Treatment ◽  
Thérapie Cellulaire ◽  
The Impact

Purpose To investigate the impact of prior-to-transplantation azacitidine (AZA) on patient outcome after allogeneic stem-cell transplantation (alloSCT) for myelodysplastic syndrome (MDS). Patients and Methods Of the 265 consecutive patients who underwent alloSCT for MDS between October 2005 and December 2009, 163 had received cytoreductive treatment prior to transplantation, including induction chemotherapy (ICT) alone (ICT group; n = 98), AZA alone (AZA group; n = 48), or AZA preceded or followed by ICT (AZA-ICT group; n = 17). At diagnosis, 126 patients (77%) had an excess of marrow blasts, and 95 patients (58%) had intermediate-2 or high-risk MDS according to the International Prognostic Scoring System (IPSS). Progression to more advanced disease before alloSCT was recorded in 67 patients. Donors were sibling (n = 75) or HLA-matched unrelated (10/10; n = 88). They received blood (n = 142) or marrow (n = 21) grafts following either myeloablative (n = 33) or reduced intensity (n = 130) conditioning. Results With a median follow-up of 38.7 months, 3-year outcomes in the AZA, ICT, and AZA-ICT groups were 55%, 48%, and 32% (P = .07) for overall survival (OS); 42%, 44%, and 29% (P = .14) for event-free survival (EFS); 40%, 37%, and 36% (P = .86) for relapse; and 19%, 20%, and 35% (P = .24) for nonrelapse mortality (NRM), respectively. Multivariate analysis confirmed the absence of statistical differences between the AZA and the ICT groups in terms of OS, EFS, relapse, and NRM. Conclusion With the goal of downstaging underlying disease before alloSCT, AZA alone led to outcomes similar to those for standard ICT.

Curative Therapy of Advanced Essential Thrombocythemia or Polycythemia Vera by Hemopoietic Stem Cell Transplantation

2002 ◽  
Vol 43 (7) ◽  
pp. 1409-1414 ◽  
Author(s):  
Uwe Platzbecker ◽  
Ted Gooley ◽  
Claudio Anasetti ◽  
Frederick R. Appelbaum ◽  
Bruce Clurman ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Polycythemia Vera ◽  
Cell Transplantation ◽  
Essential Thrombocythemia ◽  
Hemopoietic Stem Cell ◽  
Curative Therapy ◽  
Hemopoietic Stem Cell Transplantation

Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation

Blood ◽  
2003 ◽  
Vol 102 (1) ◽  
pp. 394-403 ◽  
Author(s):  
Denise A. Wells ◽  
Martin Benesch ◽  
Michael R. Loken ◽  
Carlos Vallejo ◽  
David Myerson ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Myelodysplastic Syndrome ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Scoring System ◽  
International Prognostic Scoring System ◽  
Hematopoietic Stem ◽  
Flow Cytometric

Abstract Marrow cells of myeloid lineage from 115 patients with myelodysplastic syndrome (MDS) were characterized by multidimensional flow cytometry and compared with findings in 104 patients with various disorders and 25 healthy donors. Based on phenotypic and scatter characteristics, a flow cytometric scoring system (FCSS) was developed that allowed for a simple numerical display of results. The flow cytometric scores were categorized as normal/mild (0-1), moderate (2-3), or severe (≥ 4). Most flow cytometric abnormalities were significantly (P < .05) more frequent in patients with MDS than in the control cohort. Flow cytometric scores in MDS patients were then retrospectively compared with marrow blast counts assessed by morphology, cytogenetics, hematologic parameters, and International Prognostic Scoring System (IPSS) risk categorization. The flow cytometric scores correlated inversely with leukocyte and absolute neutrophil counts (P < .01) and correlated directly with IPSS scores (P < .01) and with IPSS cytogenetic risk categories (P < .01). In 111 MDS patients who underwent allogeneic hematopoietic stem cell transplantation, flow scores correlated with posttransplantation outcome. The probabilities of posttransplantation relapse were 3%, 15%, and 33% for patients with mild, moderate, and severe FCSS scores, respectively (P < .01), and overall survival was 74%, 40%, and 36%, respectively, for the 3 groups (P < .01). In multivariate analyses, there was a significant contribution of the flow score independent of the IPSS in predicting survival and relapse (P < .01, P = .02, and P = .03, respectively). These data suggest that FCSS is useful in assessing marrows for diagnosis of MDS and in determining the prognostic outcome in patients with this disorder. (Blood. 2003;102:394-403)

Sign in / Sign up

Export Citation Format

Share Document